Literature DB >> 24237700

Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency.

Hillel Haim1, Ignacio Salas, Kathleen McGee, Noah Eichelberger, Elizabeth Winter, Beatriz Pacheco, Joseph Sodroski.   

Abstract

Efforts to prevent human immunodeficiency virus type 1 (HIV-1) infection would benefit from understanding the factors that govern virus neutralization by antibodies. We present a mechanistic model for HIV-1 neutralization that includes both virus and antibody parameters. Variations in epitope integrity on the viral envelope glycoprotein (Env) trimer and Env reactivity to bound antibody influence neutralization susceptibility. In addition, we define an antibody-specific parameter, the perturbation factor (PF), that describes the degree of conformational change in the Env trimer required for a given antibody to bind. Minimally perturbing (low-PF) antibodies can efficiently neutralize viruses with a broad range of Env reactivities due to fast on-rates and high affinity for Env. Highly perturbing (high-PF) antibodies inhibit only viruses with reactive (perturbation-sensitive) Envs, often through irreversible mechanisms. Accounting for these quantifiable viral and antibody-associated parameters helps to predict the observed profiles of HIV-1 neutralization by antibodies with a wide range of potencies.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24237700      PMCID: PMC3875163          DOI: 10.1016/j.chom.2013.10.006

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  30 in total

Review 1.  Occupancy and mechanism in antibody-mediated neutralization of animal viruses.

Authors:  P J Klasse; Q J Sattentau
Journal:  J Gen Virol       Date:  2002-09       Impact factor: 3.891

2.  Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.

Authors:  P Kolchinsky; E Kiprilov; J Sodroski
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.

Authors:  P W Parren; I Mondor; D Naniche; H J Ditzel; P J Klasse; D R Burton; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  Inhibition of the HIV-1 spike by single-PG9/16-antibody binding suggests a coordinated-activation model for its three protomeric units.

Authors:  Robin Löving; Mathilda Sjöberg; Shang-Rung Wu; James M Binley; Henrik Garoff
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

6.  Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Authors:  J R Mascola; S W Snyder; O S Weislow; S M Belay; R B Belshe; D H Schwartz; M L Clements; R Dolin; B S Graham; G J Gorse; M C Keefer; M J McElrath; M C Walker; K F Wagner; J G McNeil; F E McCutchan; D S Burke
Journal:  J Infect Dis       Date:  1996-02       Impact factor: 5.226

7.  Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera.

Authors:  T Wrin; T P Loh; J C Vennari; H Schuitemaker; J H Nunberg
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

8.  The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.

Authors:  Pavel Pugach; Shawn E Kuhmann; Joann Taylor; Andre J Marozsan; Amy Snyder; Thomas Ketas; Steven M Wolinsky; Bette T Korber; John P Moore
Journal:  Virology       Date:  2004-03-30       Impact factor: 3.616

9.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

View more
  32 in total

1.  SOSIP Changes Affect Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Conformation and CD4 Engagement.

Authors:  Nirmin Alsahafi; Sai Priya Anand; Luis Castillo-Menendez; Myriam Maude Verly; Halima Medjahed; Jérémie Prévost; Alon Herschhorn; Jonathan Richard; Arne Schön; Bruno Melillo; Ernesto Freire; Amos B Smith; Joseph Sodroski; Andrés Finzi
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

2.  Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function.

Authors:  Hanh T Nguyen; Nirmin Alsahafi; Andrés Finzi; Joseph G Sodroski
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

3.  Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.

Authors:  Peter Hraber; Bette T Korber; Alan S Lapedes; Robert T Bailer; Michael S Seaman; Hongmei Gao; Kelli M Greene; Francine McCutchan; Carolyn Williamson; Jerome H Kim; Sodsai Tovanabutra; Beatrice H Hahn; Ronald Swanstrom; Michael M Thomson; Feng Gao; Linda Harris; Elena Giorgi; Nicholas Hengartner; Tanmoy Bhattacharya; John R Mascola; David C Montefiori
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

4.  Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors.

Authors:  Beatriz Pacheco; Nirmin Alsahafi; Olfa Debbeche; Jérémie Prévost; Shilei Ding; Jean-Philippe Chapleau; Alon Herschhorn; Navid Madani; Amy Princiotto; Bruno Melillo; Christopher Gu; Xin Zeng; Youdong Mao; Amos B Smith; Joseph Sodroski; Andrés Finzi
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

5.  Conformational Differences between Functional Human Immunodeficiency Virus Envelope Glycoprotein Trimers and Stabilized Soluble Trimers.

Authors:  Luis R Castillo-Menendez; Hanh T Nguyen; Joseph Sodroski
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

6.  The lipid membrane of HIV-1 stabilizes the viral envelope glycoproteins and modulates their sensitivity to antibody neutralization.

Authors:  Hamid Salimi; Jacklyn Johnson; Manuel G Flores; Michael S Zhang; Yunxia O'Malley; Jon C Houtman; Patrick M Schlievert; Hillel Haim
Journal:  J Biol Chem       Date:  2019-11-22       Impact factor: 5.157

7.  CD4 Incorporation into HIV-1 Viral Particles Exposes Envelope Epitopes Recognized by CD4-Induced Antibodies.

Authors:  Shilei Ding; Romain Gasser; Gabrielle Gendron-Lepage; Halima Medjahed; William D Tolbert; Joseph Sodroski; Marzena Pazgier; Andrés Finzi
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

8.  Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.

Authors:  Navid Madani; Amy M Princiotto; Connie Zhao; Fatemeh Jahanbakhshsefidi; Max Mertens; Alon Herschhorn; Bruno Melillo; Amos B Smith; Joseph Sodroski
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

9.  Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States.

Authors:  Jacklyn Johnson; Yinjie Zhai; Hamid Salimi; Nicole Espy; Noah Eichelberger; Orlando DeLeon; Yunxia O'Malley; Joel Courter; Amos B Smith; Navid Madani; Joseph Sodroski; Hillel Haim
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

10.  Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.

Authors:  M Anthony Moody; Feng Gao; Thaddeus C Gurley; Joshua D Amos; Amit Kumar; Bhavna Hora; Dawn J Marshall; John F Whitesides; Shi-Mao Xia; Robert Parks; Krissey E Lloyd; Kwan-Ki Hwang; Xiaozhi Lu; Mattia Bonsignori; Andrés Finzi; Nathan A Vandergrift; S Munir Alam; Guido Ferrari; Xiaoying Shen; Georgia D Tomaras; Gift Kamanga; Myron S Cohen; Noel E Sam; Saidi Kapiga; Elin S Gray; Nancy L Tumba; Lynn Morris; Susan Zolla-Pazner; Miroslaw K Gorny; John R Mascola; Beatrice H Hahn; George M Shaw; Joseph G Sodroski; Hua-Xin Liao; David C Montefiori; Peter T Hraber; Bette T Korber; Barton F Haynes
Journal:  Cell Host Microbe       Date:  2015-09-09       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.